The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.
 
Ramya Ramaswami
No Relationships to Disclose
 
Kathryn Anne Lurain
No Relationships to Disclose
 
Priscila Hermont Goncalves
No Relationships to Disclose
 
Anaida Widell
No Relationships to Disclose
 
Matthew Lindsley
No Relationships to Disclose
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Cody J. Peer
No Relationships to Disclose
 
Seth M. Steinberg
No Relationships to Disclose
 
Vikram Khetani
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Peter L. Choyke
Patents, Royalties, Other Intellectual Property - I am a patent holder for MRI-Ultrasound fusion technology licensed to InVivo which markets it as UroNav. However, as a government employee I personally receive no financial benefit from this patent.
Other Relationship - Aspyrian Therapeutics; General Electric; Philips Healthcare
 
Joseph R Fontana
No Relationships to Disclose
 
Denise Whitby
No Relationships to Disclose
 
Thomas S. Uldrick
Research Funding - Bayer (Inst); Celgene (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - As an employee of the U.S. Government, I have provisional patent application regarding methods for the treatment of Kaposi’s sarcoma and KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (Inst)
 
Robert Yarchoan
No Relationships to Disclose